A biotech’s binary bet ends badly

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning! Elaine Chen is away, so I’m here in her stead. Take it slow out there, Northeast-ers, the outside temps are about to hit “wicked hot.”

The need-to-know this morning

• Zentalis Pharmaceuticals said the FDA placed a partial hold on clinical trials involving its experimental cancer medicine azenosertib following the deaths of two patients due to “presumed sepsis.”
• Intra-Cellular Therapies reported positive results from a second, Phase 3 clinical trial seeking to expand the use of its antipsychotic medicine Caplyta to patients with major depressive disorder. Positive results from the first Phase 3 study were reported in April.
• Taysha Gene Therapies reported preliminary results from a study of  its gene therapy for adults and children with Rett syndrome.

Ethan Weiss has raked in some cash 

Now we know what the former UCSF cardiologist and frequent Twitter/X contributor has been doing for the past few years: starting up a biotech company.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In